Disclosed are azaindazole compounds of Formula (I): or pharmaceutically acceptable salts thereof, wherein: Q is: (i) 5-membered heteroaryl comprising at least one nitrogen heteroatom and substituted with zero to 2 Rg; or (ii) 9- to 10-membered bicyclic heteroaryl selected from Formula (II) and; wherein Ring A is a 5- to 6-membered aryl or heteroaryl fused ring substituted with zero to 2 Rg; and R1, R2, R3, and Rg are defined herein. Also disclosed are methods of using such compounds in the treatment of at least one CYP17 associated condition, such as, for example, cancer, and pharmaceutical compositions comprising such compounds.
本发明涉及以下式(I)的
吡唑吡嗪化合物或其药学上可接受的盐,其中:Q为:(i)包含至少一个氮杂原子的5-成员杂芳基,取代基为零到2个Rg;或(ii)选自式(II)的9-至10-成员双环杂芳基;其中环A为5-至6-成员芳基或杂芳基融合环,取代基为零到2个Rg;R1、R2、R3和Rg如本文所定义。本发明还涉及使用这种化合物治疗至少一种CYP17相关疾病的方法,例如癌症,以及包含这种化合物的制药组合物。